Dr. Joe Edward Coker, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1800 W 1st St, Elk City, OK 73644 Phone: 580-243-2200 |
Cole Wayne Wootton, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1800 W 1st St, Suite 106, Elk City, OK 73644 Phone: 580-243-2200 Fax: 580-243-0812 |
News Archive
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.
Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.
Researchers at Rensselaer Polytechnic Institute have discovered new details about how bacteria generate energy to live. In two recently published papers, the scientists add key specifics to the molecular mechanism behind the pathogen that causes cholera.
The new METTLER TOLEDO White Paper "Traceability with Microgram Weights" describes the challenges of becoming the first calibration laboratory in the world to achieve accredited status for calibration weights in the microgram range.
› Verified 3 days ago